The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits. UTHR sticks out from CTLT in both our Zacks Rank and Style Scores models, so value investors will likely feel that UTHR is the better option right now. United Therapeutics and Catalent ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all. However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects, makes it pretty easy to find cuttingedge growth stocks. Studies have shown that stocks with the best gro ...

Given these factors, it shouldn't be surprising that UTHR is a #2 (Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep United Therapeutics on your short list. Earnings Outlook The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have re ...

Core Viewpoint - United Therapeutics (UTHR) is currently viewed as a more attractive investment option compared to Catalent (CTLT) for value investors, based on various valuation metrics and analyst outlooks [2][5]. Valuation Metrics - UTHR has a P/B ratio of 2.67, while CTLT has a P/B ratio of 2.89, indicating that UTHR is relatively undervalued compared to CTLT [4]. - The forward P/E ratio for UTHR is 12.93, significantly lower than CTLT's forward P/E of 49.05, suggesting UTHR is more favorably priced [8]. - UTHR's PEG ratio stands at 1.40, while CTLT's PEG ratio is 1.68, further supporting UTHR's position as a better value investment [8]. Analyst Outlook - UTHR holds a Zacks Rank of 2 (Buy), reflecting a positive earnings estimate revision activity, whereas CTLT has a Zacks Rank of 5 (Strong Sell), indicating a less favorable outlook [2][5]. - UTHR has a Value grade of B, while CTLT has a Value grade of D, highlighting the relative strength of UTHR in terms of value metrics [9].

Have you been paying attention to shares of United Therapeutics (UTHR) ? Shares have been on the move with the stock up 11.6% over the past month. The stock hit a new 52-week high of $330 in the previous session. United Therapeutics has gained 46.2% since the start of the year compared to the 7.5% move for the Zacks Medical sector and the -3.5% return for the Zacks Medical - Drugs industry. For the current fiscal year, United Therapeutics is expected to post earnings of $24.85 per share on $2.71 billion in ...

United Therapeutics (UTHR) announced full enrolment in the phase III TETON 2 study evaluating a nebulized version of Tyvaso (treprostinil) in patients with idiopathic pulmonary fibrosis (IPF), a scarring disease of the lungs. The TETON 2 study is now enrolled with a total of 597 patients. Top-line data from this study is expected in second-half 2025. The FDA has already approved Tyvaso as an inhalation solution (nebulized) and dry powder inhaler (DPI) for treating pulmonary arterial hypertension (PAH) and p ...

FX Empire Logo English check-icon Italiano Español Português Deutsch العربية Français Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial ...

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. What are the Zacks Style Scores? Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance t ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Z ...

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1][2] Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum, serving as complementary indicators to the Zacks Rank [3] - Stocks are rated from A to F, with A indicating the highest potential for outperformance [4] Value Score - The Value Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [4] Growth Score - The Growth Score assesses a company's future prospects through projected earnings, sales, and cash flow [5] Momentum Score - The Momentum Score identifies stocks with favorable price trends using recent price changes and earnings estimate revisions [6] VGM Score - The VGM Score combines all three Style Scores, highlighting stocks with attractive value, growth, and momentum characteristics [7] Zacks Rank - The Zacks Rank is a proprietary model based on earnings estimate revisions, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8][9] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [10] Stock to Watch: United Therapeutics (UTHR) - United Therapeutics Corporation specializes in treatments for pulmonary arterial hypertension (PAH) with four marketed medicines [12] - UTHR holds a Zacks Rank of 3 (Hold) and a VGM Score of A, with a Value Style Score of B, supported by a forward P/E ratio of 11.37 [13] - Recent upward revisions in earnings estimates have increased the Zacks Consensus Estimate to $24.20 per share, with an average earnings surprise of 12.4% [13][14]